Ali Aytac

Dr. Ali Aytac

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
STSalih Tunbekici
Salih Tunbekici
HYHaydar Çağatay Yüksel
Haydar Çağatay Yüksel
CACaner Acar
Caner Acar
GŞGökhan Şahin
Gökhan Şahin
SOSeval Orman
Seval Orman
PGPınar Gürsoy
Pınar Gürsoy
Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.

1 January 2025 in American Journal of Cancer Research
Verified
Journal Article
Closed access
AAAli Aytac
Ali Aytac
BDBilgin Demir
Bilgin Demir
OBOnur Yazdan Balcik
Onur Yazdan Balcik
TTTuba Ugur Tuzcu
Tuba Ugur Tuzcu
EOEsin Oktay
Esin Oktay
OYOzan Yazici
Ozan Yazici
The aim of this study is to determine the clinicopathologic features of KRAS mutant metastatic non-small cell lung cancer (NSCLC) patients and to determine the clinical, prognostic and survival differences between subtypes and their relationship with response to treatment. A total of 101 patients with KRAS mutant metastatic non-small cell lung cancer treated in 3 oncology centers between 2013 and 2024 were included in this retrospective, multicenter study conducted in Turkey. Molecular analysis was confirmed by next generation sequencing (NGS; QIAGEN Clinical Insight Interpretation, United States). The Kaplan-Meier method was used to compare progression-free (PFS) and overall survival (OS) times between KRAS subgroups. KRAS G12C mutation was detected in 69 (68.3%) and KRAS non-G12C mutation in 32 (31.7%) patients. In both groups, the majority of patients were male (91.3% vs. 84.4%), smokers or former smokers (92.8% vs. 90.6%) and histologically had adenocarcinoma subtype (88.4% vs. 81.3%). There was no statistically significant difference in PD-L1 expression (21.7% vs. 34.4%, P: 0.132). In the KRAS non-G12C group, the most common mutations were G12V 15 (14.8%) and G12D 6 (5.9%). The most common co-mutation accompanying KRAS G12C mutation was TP53 (23%), while the most common co-mutation accompanying KRAS non-G12C was Rictor (36.3%). While 23 (33.3%) patients with KRAS G12C mutation developed brain metastasis, this rate was 14 (43.8%) in the KRAS non-G12C mutation group (P=0.312). Median follow-up was 15.30 (0.3-112.0) months. The objective response rate (ORR) with first-line treatment was 47.5% in the KRAS G12C group and 48.3% in the KRAS non-G12C group (P: 0.657). Median PFS was 4.46 (2.85-6.08) months in the KRAS G12C group and 5.23 (3.46-6.99) months in the KRAS non-G12C group (P: 0.852). Median overall survival was 14.46 (8.34-20.58) months in the KRAS G12C group and 15.36 (5.01-25.71) months in the KRAS non-G12C group (P: 0.201). In KRAS mutant metastatic NSCLC patients, no significant difference was found between KRAS subtypes (G12C vs. non-G12C) in terms of clinical, prognostic and survival data.

22 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BKBaris Koksal
Baris Koksal
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
DGDeniz Can Guven
Deniz Can Guven
FKFatih Köse
Fatih Köse
GKGörkem Köymen
Görkem Köymen
ZAZafer ARIK
Zafer ARIK
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in Türkiye between January 2014 and March 2025. Clinical, pathological, and molecular data—including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification—was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan–Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3–4 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.

17 November 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
STSalih Tunbekici
Salih Tunbekici
GŞGökhan Şahin
Gökhan Şahin
HYHaydar Çağatay Yüksel
Haydar Çağatay Yüksel
CACaner Acar
Caner Acar
IAImge Akın
Imge Akın
EGERDEM GOKER
ERDEM GOKER
Background Uterine leiomyosarcoma is a rare and aggressive malignancy with limited responsiveness to standard therapies. We conducted a real-world, multicenter study to compare the clinical efficacy and safety of two commonly used first-line chemotherapy regimens—doxorubicin–ifosfamide and gemcitabine–docetaxel—in patients with metastatic uterine leiomyosarcoma. Methods This retrospective cohort included 271 patients with advanced or metastatic uterine leiomyosarcoma treated between 2010 and 2023 across 30 centers in Turkey. Patients received either doxorubicin–ifosfamide (n = 142) or gemcitabine–docetaxel (n = 129) as first-line therapy. The primary endpoint was overall survival; secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Adverse events were graded according to the Common Terminology Criteria for Adverse Events version 5.0, while survival outcomes were estimated using the Kaplan–Meier method and further analyzed with Cox proportional hazards models. Results Median overall survival was 19.7 months with doxorubicin–ifosfamide and 20.2 months with gemcitabine–docetaxel (P = .26). Median progression-free survival was 5.5 months with doxorubicin–ifosfamide and 7.0 months with gemcitabine–docetaxel (P = .62). The objective response rate was numerically higher with gemcitabine–docetaxel (35% vs. 26%), although not statistically significant (P = .11). Grade 3–4 neutropenia (16% vs. 12%) and febrile neutropenia (7% vs. 6%) were more frequent with doxorubicin–ifosfamide. Conclusions In this largest-to-date real-world cohort of metastatic uterine leiomyosarcoma, doxorubicin–ifosfamide and gemcitabine–docetaxel demonstrated comparable survival outcomes. Gemcitabine–docetaxel, however, was associated with a more favorable hematologic safety profile. These findings support the clinical utility of both regimens while underscoring the need for prospective, biomarker-driven studies to refine treatment selection and improve personalization in this rare malignancy.

29 October 2023 in Acta Medica Alanya
Verified
Journal Article
Open access
OBOnur Yazdan Balçik
Onur Yazdan Balçik
AAAli Aytac
Ali Aytac
TATUGAY AVCI
TUGAY AVCI
BDBilgin Demir
Bilgin Demir
YIYusuf İlHan
Yusuf İlHan
AEATIKE PINAR ERDOGAN
ATIKE PINAR ERDOGAN
Aim: Non-small cell lung cancer (NSCLC) is one of the 3 most common and deadly cancers. The aim of the current study is to investigate whether Prognostic Nutritional Index /PNI), Systemic Immune-Inflammation Index (SIRI), Lung Immune Prognostic Index (LIPI) has a prognostic significance in patients with metastatic NSLCL. Methods: Patients diagnosed with pathologically confirmed metastatic NSCLC in 5 different hospitals in Turkey between 2016-2022 were included in our study and analyzed retrospectively. overall survival (OS) and progression-free survival (PFS) were recorded. Results: The median PFS was 5.50 months, while the median OS was 16.03 months. Median OS was 14.86 months for the PNI-Low group and 17.2 months for the PNI-High group (p: <0.121). The median OS of the PNI-Low group was shorter than the PNI-High group, but there was no statistically significant difference between the groups. Median OS was 19.86 months for the SIRI-Low group and 14.23 months for the SIRI-High group (p: <0.112). Median OS was 17.76, 15.13, 13.73 months for the LIPI-Low, LIPI-intermediate group and LIPI-high group, there was no statistically significant difference between the groups (p: <0.391) Conclusion: In conclusion, PNI and SIRI may be significant in a prospective study in a specific patient group to be performed with a larger number of patients to predict the prognosis of patients with metastatic NSCLC.

31 October 2024 in Acta Haematologica Oncologica Turcica
Verified
Journal Article
Closed access
AAAli Aytac
Ali Aytac
BDBilgin Demir
Bilgin Demir
SBSabri Barutca
Sabri Barutca
YYYakup Yürekli
Yakup Yürekli
Impact of Primary Tumor Diameter and SUVmax on Pathological Lymph Node Involvement in Non-small Cell Lung Cancer - Acta Haematologica Oncologica Turcica